<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023124</url>
  </required_header>
  <id_info>
    <org_study_id>ISG STRADA 2016</org_study_id>
    <nct_id>NCT03023124</nct_id>
  </id_info>
  <brief_title>Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor</brief_title>
  <acronym>STRADA</acronym>
  <official_title>Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized study for the comparison of trabectedin versus doxorubicin plus
      dacarbazine in patients with advanced solitary fibrous tumor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with solitary fibrous tumor will be randomized to receive 6 cycles of trabectedin or
      doxorubicin plus dacarbazine.

      In case of progression or unacceptable toxicity while under the experimental treatment prior
      to the completion of the 6 cycles, the patients will be offered to cross to the other arm
      (trabectedin arm to doxorubicin plus dacarbazine arm and vice versa).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2018</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Tumor Response Rate</measure>
    <time_frame>From the date of randomization until the date of first documented progression or date of death from any cause, whichever came first assessed up to 54 weeks.</time_frame>
    <description>evaluate the activity of trabectedin and of adriamycin in combination with dacarbazine, according to Response Evaluation Criteria in Solid Tumor (RECIST), version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Choi Response Rate</measure>
    <time_frame>week 6, week 12, week 18, then every 12 weeks up to 54 weeks</time_frame>
    <description>Percentage of patient who experienced Complete or Partial Responses after treatment according to Choi Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From enrollment up to 5 years</time_frame>
    <description>Time from the date of enrollment to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Survival free of progressive disease evaluated from enrollment up to progression according to RECIST, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>week 6, week 12, week 18, then every 12 weeks up to 54 weeks</time_frame>
    <description>Percentage of patients who have achieved complete response, partial response or stable disease ≥ 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by RECIST after the cross over</measure>
    <time_frame>week 18, week 24, week 30, week 36 and then every 12 weeks up to 54 weeks</time_frame>
    <description>Percentage of patient who experienced Complete or Partial Responses according RECIST 1.1 after cross over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) after cross over up to progression according to RECIST, or death</measure>
    <time_frame>From date of cross over until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks</time_frame>
    <description>Survival free of progressive disease evaluated from</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety according to Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>From enrollment every 3 weeks up to 54 weeks</time_frame>
    <description>Safety profile of the treatment evaluated according to Common Terminology Criteria for Adverse Events version 4.03</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solitary Fibrous Tumors</condition>
  <arm_group>
    <arm_group_label>Trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>trabectedin: 1.5 mg/m² - 1.3 mg/m² given in 24-hour continuous infusion every 21 days for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adriamycin and Dacarbazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adriamycin: 75 mg/m2/day, bolus, day 1 every 21 days for 6 cycles Dacarbazine: 400 mg/m2/day, days 1, 2 every 21 days for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Treatment with trabectedin repeated every 21 days for 6 cycles</description>
    <arm_group_label>Trabectedin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>Treatment with Adriamycin at day 1 every 21 days for 6 cycles</description>
    <arm_group_label>Adriamycin and Dacarbazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles</description>
    <arm_group_label>Adriamycin and Dacarbazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient or legal representative must be able to read and understand the informed
             consent form (ICF) and must have been willing to give written informed consent and any
             locally required authorisation before any study-specific procedures, including
             screening evaluations, sampling, and analyses.

          2. Age ≥18 years

          3. Histological centrally and molecularly confirmed diagnosis of solitary fibrous tumor
             (inclusive of the last available tumor sample)

          4. Locally advanced disease (i.e. surgical resection of local disease unfeasible
             radically, or unaccepted by the patient, or amenable to become less demolitive, or
             feasible, or easier, after cytoreduction) and/or metastatic disease

          5. Measurable or evaluable disease with RECIST

          6. Evidence of progression by RECIST during the 6 months before study entry

          7. Patients must be cytotoxic chemotherapy naïve (patients treated with
             neoadjuvant/adjuvant chemotherapy cannot be included) or could have received a
             previous target agent in front-line setting.

          8. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

          9. Adequate bone marrow function

         10. Adequate organ function

         11. Cardiac ejection fraction ≥50% as measured by echocardiogram

         12. Female patients of child-bearing potential must have negative pregnancy test within 7
             days before initiation each cycle of chemotherapy. Post-menopausal women must be
             amenorrhoeic for at least 12 months to be considered of non-childbearing potential.
             Male and female patients of reproductive potential must agree to employ an effective
             method of birth control throughout the study.

         13. No history of arterial and/or venous thromboembolic event within the previous 12
             months.

        Exclusion Criteria:

          1. Any prior treatment with cytotoxic chemotherapy

          2. &gt;1 line of anticancer targeted agents

          3. Previous treatment with any other investigational or not investigational agents within
             14 days of first day of study drug dosing

          4. Previous treatment with radiation therapy within 14 days of first day of study drug
             dosing, or patients who have not recovered from adverse events due to agents
             previously administered

          5. Previous radiotherapy to 25 % of the bone marrow

          6. Major surgery within 4 weeks prior to study entry

          7. Other primary malignancy with &lt;5 years clinically assessed disease-free interval,
             except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged
             to entail a low risk of relapse

          8. Pregnancy or breast feeding

          9. Cardiovascular diseases resulting in a New York Heart Association Functional Status &gt;2
             (24). Medical history of a myocardial infarction &lt; 6 months prior to initiation of
             study treatment

         10. Medical history of arterial thrombotic or embolic events such as cerebrovascular
             accident (including transient ischemic attacks), or pulmonary embolism within 6 months
             prior to the initiation of study treatment

         11. Known history of human immunodeficiency virus infection

         12. Active or chronic hepatitis B or C requiring treatment with antiviral therapy

         13. Medical history of hemorrhage or a bleeding event ≥ Grade 3 (NCI‐CTCAE v 4.0) within 4
             weeks prior to the initiation of study treatment

         14. Evidence of any other serious or unstable illness, or medical, psychological, or
             social condition, that could jeopardize the safety of the subject and/or his/her
             compliance with study procedures, or may interfere with the subject's participation in
             the study or evaluation of the study results

         15. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation of the study drugs

         16. Expected non-compliance to medical regimens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Stacchiotti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Italian Sarcoma Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuela Marchesi</last_name>
    <phone>+390516366</phone>
    <phone_ext>470</phone_ext>
    <email>emanuela.marchesi@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <email>silvia.stacchiotti@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
      <phone>+3902225411123</phone>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Giaccone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Badalamenti, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S. Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.</citation>
    <PMID>26022454</PMID>
  </reference>
  <reference>
    <citation>Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983 Mar;22(3):167-70.</citation>
    <PMID>6682161</PMID>
  </reference>
  <reference>
    <citation>Stacchiotti S, Libertini M, Negri T, Palassini E, Gronchi A, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S, Casali PG. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013 Jul;49(10):2376-83. doi: 10.1016/j.ejca.2013.03.017. Epub 2013 Apr 6.</citation>
    <PMID>23566418</PMID>
  </reference>
  <reference>
    <citation>Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, Gronchi A, Pilotti S, Zaffaroni N, Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res. 2013 Sep 15;19(18):5192-201. doi: 10.1158/1078-0432.CCR-13-0776. Epub 2013 Jul 25.</citation>
    <PMID>23888069</PMID>
  </reference>
  <reference>
    <citation>Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC, Lazar AJ, Wang WL, Benjamin RS, Araujo DM. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res. 2013 May 11;3(1):7. doi: 10.1186/2045-3329-3-7.</citation>
    <PMID>23663788</PMID>
  </reference>
  <reference>
    <citation>Chaigneau L, Kalbacher E, Thiery-Vuillemin A, Fagnoni-Legat C, Isambert N, Aherfi L, Pauchot J, Delroeux D, Servagi-Vernat S, Mansi L, Pivot X. Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare Tumors. 2011 Jul 11;3(3):e29. doi: 10.4081/rt.2011.e29. Epub 2011 Jul 18.</citation>
    <PMID>22066036</PMID>
  </reference>
  <reference>
    <citation>Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer. 2015 Oct 15;15:700. doi: 10.1186/s12885-015-1697-8.</citation>
    <PMID>26472661</PMID>
  </reference>
  <reference>
    <citation>Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs. 2010 Apr;28(2):199-202. doi: 10.1007/s10637-009-9249-1. Epub 2009 Apr 8.</citation>
    <PMID>19352594</PMID>
  </reference>
  <reference>
    <citation>Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011 Nov 1;117(21):4939-47. doi: 10.1002/cncr.26098. Epub 2011 Apr 8.</citation>
    <PMID>21480200</PMID>
  </reference>
  <reference>
    <citation>Valentin T, Fournier C, Penel N, Bompas E, Chaigneau L, Isambert N, Chevreau C. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs. 2013 Dec;31(6):1626-7. doi: 10.1007/s10637-013-0023-z. Epub 2013 Sep 5.</citation>
    <PMID>24005614</PMID>
  </reference>
  <reference>
    <citation>Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, Gronchi A, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG, Zaffaroni N. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur J Cancer. 2014 Nov;50(17):3021-8. doi: 10.1016/j.ejca.2014.09.004. Epub 2014 Sep 27.</citation>
    <PMID>25269954</PMID>
  </reference>
  <reference>
    <citation>Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16.</citation>
    <PMID>27185843</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solitary Fibrous Tumors</mesh_term>
    <mesh_term>Neoplasms, Fibrous Tissue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

